As the Authority needs additional time to reach a conclusion on the risk assessment of the active substances acequinocyl, emamectin and fatty acids C7 to C20, the duration of the extension of the approval period for these active substances should be set at 23 months and 2 weeks. For the active substance pendimethalin, 2 additional months are necessary to finalise the public consultation pursuant to Article 12 of Implementing Regulation (EU) 2020/1740, therefore the extension of the approval period for this active substance should be set at 25 months and 2 weeks.
Recital 12, Regulation (EU) 2024/2221
In forcesince 6 Sep 2024